Bioline Rx Ltd

Research Bioline Rx Ltd (BLRX) on Bullrun: market cap USD 13.49M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBLRX
• ExchangeNASDAQ
• CountryIsrael
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 13.49M
• Financial periodQ1 2026
• RevenueUSD 477.00K
• Net income-USD 1.60M
• Free cash flow-USD 2.29M
• Gross margin80.1%

Valuation Snapshot

latest market cap is USD 13.49M.

About Bioline Rx Ltd

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

Frequently asked questions

What is Bioline Rx Ltd's market cap?

Bioline Rx Ltd's market capitalization is USD 13.49M.

What does Bioline Rx Ltd do?

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers;